{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:42:18Z","timestamp":1792233738781,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jval.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:27:03Z","timestamp":1787066823000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Drug Monitoring Guided Vedolizumab Treatment in Ulcerative Colitis in Cyprus: A Cost-Effectiveness Analysis"],"prefix":"10.1016","author":[{"given":"Olga","family":"Pitsillidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petya","family":"Milushewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pitsillidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Filippou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Gavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.07.009_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2020.09.006","article-title":"Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease","volume":"55","author":"McNeill","year":"2020","journal-title":"Curr Opin Pharmacol"},{"issue":"10401","key":"10.1016\/j.jval.2026.07.009_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jval.2026.07.009_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/medsci13030117","article-title":"Disease burden and unmet medical needs in patients with ulcerative colitis in Greece: a cross-sectional patient survey","volume":"13","author":"Gourzoulidis","year":"2025","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"10.1016\/j.jval.2026.07.009_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jval.2026.07.009_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2026.07.009_bib6","first-page":"14","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"12","key":"10.1016\/j.jval.2026.07.009_bib7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2026.07.009_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure\u2014response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study","volume":"56","author":"Vande Casteele","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jval.2026.07.009_bib9","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/bcp.16164","article-title":"Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: a systematic review","volume":"90","author":"Carland","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jval.2026.07.009_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/pharmaceutics15030972","article-title":"Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease patients during maintenance treatment-TUMMY study","volume":"15","author":"Sivrida\u015f","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jval.2026.07.009_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.jval.2026.07.009_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s41669-022-00331-9","article-title":"Cost effectiveness of subcutaneous vedolizumab for maintenance treatment of ulcerative colitis in Canada","volume":"6","author":"Fenu","year":"2022","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"10.1016\/j.jval.2026.07.009_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.jval.2026.07.009_bib15","doi-asserted-by":"crossref","first-page":"i2248","DOI":"10.1093\/ecco-jcc\/jjae190.1416","article-title":"P1242 incidence of acute severe ulcerative colitis in a changing landscape of increased disease prevalence and more effective therapies","volume":"19","author":"Nario","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"issue":"4","key":"10.1016\/j.jval.2026.07.009_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bcpt.13983","article-title":"Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: a snapshot of laboratories and applications across Europe","volume":"134","author":"Skrede","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.jval.2026.07.009_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.jval.2026.07.009_bib19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jval.2026.07.009_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jval.2026.07.009_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and \u22122 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"23","key":"10.1016\/j.jval.2026.07.009_bib22","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2026.07.009_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1478-7547-7-20","article-title":"Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis","volume":"7","author":"Xie","year":"2009","journal-title":"Cost Eff Resour Alloc C E"},{"issue":"11","key":"10.1016\/j.jval.2026.07.009_bib24","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.cgh.2014.03.012","article-title":"Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis","volume":"12","author":"Ung","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.07.009_bib38","article-title":"The relation between disease activity, quality of life and health utility in patients with ulcerative colitis","volume":"57","author":"Woehl","year":"2008","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jval.2026.07.009_bib25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14737167.2023.2237684","article-title":"Implementing a managed entry agreement framework in Cyprus","volume":"23","author":"Pitsillidou","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2026.07.009_bib26","series-title":"Decision Modelling for Health Economic Evaluation","first-page":"250","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2026.07.009_bib27","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"3","key":"10.1016\/j.jval.2026.07.009_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/0272989X15586552","article-title":"Interpretation of the expected value of perfect information and research recommendations: a systematic review and empirical investigation","volume":"36","author":"Thorn","year":"2016","journal-title":"Med Decis Mak"},{"issue":"23","key":"10.1016\/j.jval.2026.07.009_bib29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jval.2026.07.009_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ibd\/izaa073","article-title":"A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to anti-TNF therapy","volume":"27","author":"Yao","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.07.009_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10620-024-08802-1","article-title":"Therapeutic drug monitoring in patients with ulcerative colitis on infliximab: a cost-effectiveness analysis","volume":"70","author":"Dupenloup","year":"2025","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.jval.2026.07.009_bib32","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.07.009_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12248-025-01050-9","article-title":"Therapeutic drug monitoring of biologics: current practice, challenges and opportunities\u2014a workshop report","volume":"27","author":"Shubow","year":"2025","journal-title":"AAPS J"},{"issue":"14","key":"10.1016\/j.jval.2026.07.009_bib34","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2026.07.009_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bcp.14494","article-title":"A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments","volume":"87","author":"Vithanachchi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jval.2026.07.009_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/FTD.0000000000001010","article-title":"The appropriately designed TDM clinical trial: endpoints, pitfalls, and perspectives","volume":"45","author":"van Gelder","year":"2023","journal-title":"Ther Drug Monit"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602591X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152602591X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:49:50Z","timestamp":1792230590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152602591X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S109830152602591X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Drug Monitoring Guided Vedolizumab Treatment in Ulcerative Colitis in Cyprus: A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}